Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013)

Bibliography

• Clayton AL, Hazzalin CA, Mahadevan LC. Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell 2006;23:289-96
   PubMed Web of Science ®Google Scholar
• Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008;9:206-18
   PubMed Web of Science ®Google Scholar
• Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009;10:32-42
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51
   PubMed Web of Science ®Google Scholar
• Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-32
   PubMed Web of Science ®Google Scholar
• Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010;19:1049-66
   PubMed Web of Science ®Google Scholar
• Lahm A, Paolini C, Pallaoro M, et al. Unraveling the hidden catalytic activity of vertebrateclass IIa histone deacetylases. Proc Natl Acad Sci USA 2007;104:17335-40
   PubMed Web of Science ®Google Scholar
• Boyault C, Sadoul K, Pabion M, et al. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007;26:5468-76
   PubMed Web of Science ®Google Scholar
• Milne JC, Denu JM. The sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol 2008;12:11-17
   PubMed Web of Science ®Google Scholar
• Outeiro TF, Marques O, Kazantsev A. Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta 2008;1782:363-9
   PubMed Web of Science ®Google Scholar
• Yao Y, Yang Y, Zhu WG. Sirtuins: nodes connecting aging, metabolism and tumorigenesis. Curr Pharm Des 2013; Epub ahead of print
   Google Scholar
• Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92:1300-4
   PubMedGoogle Scholar
• Zhang Z, Yamashita H, Toyama T, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat 2005;94:11-16
   PubMed Web of Science ®Google Scholar
• Rikimaru T, Taketomi A, Yamashita Y, et al. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 2011;72:69-74
   Google Scholar
• Fritzsche FR, Weichert W, Roske A, et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 2008;8:381
   Google Scholar
• Miyake K, Yoshizumi T, Imura S, et al. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008;36:e1-9
   PubMed Web of Science ®Google Scholar
• Weichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98:604-10
   PubMed Web of Science ®Google Scholar
• Ropero S, Fraga MF, Ballestar E, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 2006;38:566-9
   PubMed Web of Science ®Google Scholar
• Chang HH, Chiang CP, Hung HC, et al. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 2009;45:610-14
   PubMed Web of Science ®Google Scholar
• Krusche CA, Wulfing P, Kersting C, et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005;90:15-23
   PubMed Web of Science ®Google Scholar
• Moreno DA, Scrideli CA, Cortez MA, et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol 2010;150:665-73
   PubMed Web of Science ®Google Scholar
• Ozdağ H, Teschendorff AE, Ahmed AA, et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006;7:90
   PubMed Web of Science ®Google Scholar
• Gloghini A, Buglio D, Khaskhely NM, et al. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol 2009;147:515-25
   PubMed Web of Science ®Google Scholar
• Oehme I, Deubzer HE, Lodrini M, et al. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs 2009;18:1605-17
   PubMed Web of Science ®Google Scholar
• Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2012;31:537-51
   Google Scholar
• Dinarello CA. Anti-inflammatory agents: present and future. Cell 2010;140:935-50
   PubMed Web of Science ®Google Scholar
• Gray SG. Epigenetic treatment of neurological disease. Epigenomics 2011;3:431-50
   PubMed Web of Science ®Google Scholar
• Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003;46:5097-116
   PubMed Web of Science ®Google Scholar
• Mai A, Massa S, Rotili D, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005;25:261-309
   PubMed Web of Science ®Google Scholar
• Venugopal B, Evans TR. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 2011;18:1658-71
   Google Scholar
• Available from: http://www.fda.gov/default.htm
   Google Scholar
• Available from: http://clinicaltrials.gov
   Google Scholar
• Available from: http://www.4sc.de/product-pipeline/clinical/4sc-201(or 4sc-202)
   Google Scholar
• Stühmer T, Arts J, Chatterjee M. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. Br J Haematol 2010;149:529-36
   PubMed Web of Science ®Google Scholar
• Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012;119:2579-89
   PubMed Web of Science ®Google Scholar
• Moffat D, Patel S, Day F, et al. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl) methyl] amino} bicyclo [3.1. 0] hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J Med Chem 2010;53:8663-78
   PubMed Web of Science ®Google Scholar
• Available from: https://ash.confex.com/ash/2010/webprogram/Paper28495.html
   Google Scholar
• Banerji U, van Doorn L, Papadatos-Pastos D, et al. Phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res 2012;18:2687-94
   Google Scholar
• Jacob A, Oblinger J, Bush ML, et al. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope 2012;122(1):174-89
   Google Scholar
• New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 2012;6:637-56
   PubMed Web of Science ®Google Scholar
• Kozikowski A, Butler KB, Kalin JH. HDAC inhibitors and therapeutic methods using the same. WO011186A2; 2011
   Google Scholar
• Haggarty SJ, Koeller KM, Wong JC, et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003;100:4389-94
   PubMed Web of Science ®Google Scholar
• Kozikowski A, Butler KB, Kalin JH, et al. HDAC inhibitors and therapeutic methods using the same. WO106343A2; 2012
   Google Scholar
• Selvakumar N, Rajulu GG, Pazhanimuthu A, et al. Histone deacetylase inhibitors. WO021209A1; 2011
   Google Scholar
• Cossio Mora FP, Zubia Olascoaga A, Vara Salazar YI, et al. New histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers. EP2305643A1; 2011
   Google Scholar
• Cossio Mora FP, Vara Salazar YI, San Sebastian Larzabal E, et al. Hydroxyphenylpyrrole compounds containing an hydroxamic acid as HDAC inhibitors and medicinal applications thereof. EP2508510A1; 2012
   Google Scholar
• Varasi M, Thaler F, Amici R, et al. Spirocyclic derivatives as histone deacetylase inhibitors. EP2311840A1; 2011
   Google Scholar
• Varasi M, Thaler F, Amici R, et al. Spirocyclic derivatives as histone deacetylase inhibitors. WO045265A2; 2011
   Google Scholar
• Breslow R, Marks PA, Abhilash KG, et al. Selective HDAC inhibitors. WO146855A1; 2011
   Google Scholar
• Bao R, Lai C, Qian C. Treatment of cancers having K-Ras mutations. WO130628A1; 2011
   Google Scholar
• Donald ADG, Moffat DFC, Belfield AJ, et al. Alpha, alpha-disubstituted glycine ester derivatives and their use as HDAC inhibitors. WO025701A1; 2012
   Google Scholar
• Oyelere A, Gryder B. Histone deacetylase inhibitors targeting prostate tumors and methods of making and using thereof. WO050868A1; 2012
   Google Scholar
• Chen Y, Chen Y. HDAC inhibiting derivatives of Camptothecin. WO096832A2; 2012
   Google Scholar
• Lin X, Qiu Z, Tang G, et al. Novel 4-amino-N-hydroxy benzamides as HDAC inhibitors for the treatment of cancer. WO098132A1; 2012
   Google Scholar
• Luckhurst CA, Haughan AF, Breccia P, et al. Histone deacetylase inhibitors and compositions and methods of use thereof. WO103008A1; 2012
   Google Scholar
• Abeywickrama C, Bradner JE, Ponnala S. Selective inhibitors of histone deacetylase isoform 6 and methods thereof. WO178208A2; 2012
   Google Scholar
• Kim Y, Lee C, Yang HM, et al. Hydroxamate derivatives for HDAC inhibitors, and the pharmaceutical composition comprising thereof. WO062344A1; 2013
   Google Scholar
• Giannini G, Cabri W, Battistuzzi G, et al. New thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments. WO041480A1; 2013
   Google Scholar
• Grigg RE, Inman M, Packham G. N-(2-aminophenyl) benzamide derivatives as histone deacetylase inhibitors. WO005049A1; 2013
   Google Scholar
• De Zoeten EF, Wang L, Sai H, et al. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 2010;138:583-94
   PubMed Web of Science ®Google Scholar
• Baloglu E, Ghosh S, Lobera M, et al. Compounds and methods. WO088192A1; 2011
   Google Scholar
• Ghosh S, Lobera M, Schmidt D. Compounds and methods. WO006408A1; 2013
   Google Scholar
• Ghosh S, Lobera M, Trump RP. Compounds and methods. WO066835A2; 2013
   Google Scholar
• Ghosh S, Lobera M, Pohlhaus DT, et al. Compounds and methods. WO066831A1; 2013
   Google Scholar
• Ghosh S, Lobera M, Trump RP, et al. Compounds and methods. WO066832A1; 2013
   Google Scholar
• Ghosh S, Lobera M, Trump RP, et al. Compounds and methods. WO066833A1; 2013
   Google Scholar
• Ghosh S, Lobera M, Trump RP, et al. Compounds and methods. WO066834A1; 2013
   Google Scholar
• Ghosh S, Lobera M, Pohlhaus DT, et al. Compounds and methods. WO066836A1; 2013
   Google Scholar
• Ghosh S, Lobera M, Trump RP, et al. Compounds and methods. WO066838A1; 2013
   Google Scholar
• Ghosh S, Lobera M, Trump RP, et al. Compounds and methods. WO066839A2; 2013
   Google Scholar
• Li J, Li G, Xu W. Histone deacetylase inhibitors: an attractive strategy for cancer therapy. Curr Med Chem 2013;20:1858-86
   Google Scholar
• Marchion DC, Bicaku E, Daud AI, et al. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004;92:223-37
   PubMed Web of Science ®Google Scholar
• Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15:5250-7
   PubMed Web of Science ®Google Scholar